Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study provides evidence supporting the feasibility of presurgical, window-of-opportunity models to evaluate the preventive potential of candidate agents in cancer, using cases from breast, prostate, and colorectal settings.

This article discusses the potential role and mechanisms of platelet-rich fibrin therapies in androgenetic alopecia management, exploring their possible benefits over existing treatments but reports no new clinical results.

This study observed that both polynucleotides (PN HPT™) and platelet-rich plasma (PRP) improved hair density and quality in men with androgenetic alopecia, with comparable outcomes and no significant adverse events.

This review discusses recent clinical trials on the use of platelet rich plasma for treating androgenetic alopecia and reports mixed findings on its effectiveness compared to standard treatments.

In this study, researchers administered injectable platelet-rich fibrin (i-PRF) to 30 patients with androgenetic alopecia, finding an 80% response rate after 6 months, with improved hair density and reduced scalp symptoms, while reporting minimal adverse reactions.

This study analyzed data from the FDA Adverse Event Reporting System and found that enfortumab vedotin, used for urothelial carcinoma, is linked to various cutaneous adverse events, including severe reactions like Stevens–Johnson syndrome, typically occurring early in treatment and predominantly affecting elderly male patients.

In the phase 3 CAPItello-291 trial, capivasertib combined with fulvestrant significantly increased progression-free survival in patients with advanced breast cancer with specific genetic alterations, but the authors highlight that managing side effects like diarrhea, rash, and hyperglycemia is crucial for optimizing treatment adherence and outcomes.

This review of studies on prostate cancer chemoprevention in Europe reports no robust evidence supporting the effectiveness of chemopreventive agents, though vitamin E and selenium may potentially contribute to prevention efforts.

In this study, subdermal platelet-rich plasma injections significantly increased hair count and shaft caliber in individuals with androgenetic alopecia, with monthly treatments potentially offering greater benefits.

This review highlights recent progress in developing androgen receptor degraders, such as PROTACs, for treating castration-resistant prostate cancer, and notes that several have entered phase I or II clinical trials, showcasing potential to address drug resistance challenges.

In this study, PRP treatment for scalp hair restoration, combined with finasteride and minoxidil, resulted in reduced hair fall, stronger hair, and satisfactory regrowth in patients, with a satisfaction level of up to 90%.

The treatment showed promising hair growth results but needs more research.

This study found that a 14-day treatment with proxalutamide significantly reduced the 28-day mortality rate in hospitalized COVID-19 patients compared to placebo, with greater benefits observed among those who adhered to the treatment.

5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.

Finasteride reduces bleeding risk during prostate surgery.

PRP shows promise for treating certain types of hair loss.

PRP preparation partially activates platelets, causing varied growth factor release.

This study evaluated the effectiveness of follicular units and growth factors derived from autologous platelet-rich plasma in improving hair growth and density in 23 male patients with pattern hair loss.

This case report challenges the traditional view by documenting reversible vision loss following scalp injections of platelet-rich plasma, attributed to an inflammatory or microvascular event, treatable with corticosteroids.

Finasteride may help prevent prostate cancer.

This study developed a simple method to prepare highly concentrated, resting platelet-rich plasma suitable for cell therapy, effectively preventing clotting while maintaining platelet reactivity and minimizing hemorrhage risk.

This article reviews the historical development of finasteride's approval for benign prostatic hyperplasia and discusses a trial that found decreased low-grade prostate cancer incidence but increased high-grade prostate cancer, with differing expert opinions on its use for cancer prevention.

This analysis concluded that preoperative finasteride significantly reduced blood loss during transurethral resection of the prostate by potentially decreasing the expression of VEGF and microvessel density.

This review discusses the evidence for platelet-rich plasma as a promising treatment for androgenetic alopecia, highlighting its potential benefits and favorable safety profile but noting the need for standardized protocols and larger trials.

This study found that PRP therapy resulted in better hair growth and patient satisfaction than minoxidil therapy in men with androgenetic alopecia over six months, and patients with higher platelet counts in PRP experienced greater improvement.

This retrospective study found that treatment with autologous plasma rich in growth factors increased hair density and improved hair follicle health in patients with androgenetic alopecia, with no reported adverse effects.

This study found that prevelex coatings on microwell array devices enhanced the formation of uniform cell spheroids and enabled the development of hair follicles in tissue engineering applications.

This study's meta-analysis reported that PRP injections significantly increased hair density compared to baseline and placebo in androgenetic alopecia patients, supporting its use as a beneficial treatment.

This study concluded that in female pattern hair loss patients, CGF and i-PRF treatments were more effective than PRP in increasing target area hair count, with i-PRF having the lowest adverse event rate.